← Leaderboards
Gaurav Das Gaiha
Massachusetts General Hospital
$9,237,997
Attributed
$9,237,997
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.8M · FY2019–25$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,237,997 · 4
By mechanism
DP1$3,507,000 · 1
DP2$2,680,145 · 1
R01$2,651,252 · 1
K08$399,600 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Todd M Allen$28,600,717
- Marcus Altfeld$19,256,149
- Beth Ann Stevens$21,074,664
- Mathias Lichterfeld$34,368,889
- Bruce D Walker$50,324,331
Others in their field
Other Emerging Leaders on “Pathway Analysis”
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
- Priyamvada Acharya · Duke University$20,941,151
- Ashlin Bolton · Broad Institute, Inc.$19,699,069
- Leigh A Johnson · University Of North Texas Hlth Sci Ctr$14,236,023
- Bjorn E Oskarsson · Mayo Clinic Jacksonville$11,846,278
- Abraham Aizer Brody · New York University School Of Medicine$11,132,986
Research focus
Pathway AnalysisAllelesVaccinesT Cell ResponseEpitopesT-Lymphocyte EpitopesStructureHiv VaccineProtein StructureProteomeInnovationResistance MutationLifeTheoriesUnited States National Institutes Of HealthViralCellsPreventModalityEpidemicMutationMissionCytotoxic T-LymphocytesAlgorithms
Grant awards (14)
Harnessing Highly Networked HLA-E-Restricted CTL Epitopes to Achieve a Broadly Effective HIV Cure$1,169,000
DP1 · FY2025 · DA · contact PI
" Investigating the Protective Efficacy of SIV/HIV T and B cell Immunity Induced by RNA Replicons.â$865,387
R01 · FY2025 · AI · contact PI
Harnessing Highly Networked HLA-E-Restricted CTL Epitopes to Achieve a Broadly Effective HIV Cure$1,169,000
DP1 · FY2024 · DA · contact PI
Investigating the Protective Efficacy of SIV/HIV T and B cell Immunity Induced by ChAd and mRNA$859,455
R01 · FY2024 · AI · contact PI
Exploiting Highly Networked CTL Epitopes to Achieve a Functional HIV Cure$499,920
DP2 · FY2024 · AI · contact PI
Harnessing Highly Networked HLA-E-Restricted CTL Epitopes to Achieve a Broadly Effective HIV Cure$1,169,000
DP1 · FY2023 · DA · contact PI
Investigating the Protective Efficacy of SIV/HIV T and B cell Immunity Induced by RNA Replicons$926,410
R01 · FY2023 · AI · contact PI
Exploiting Highly Networked CTL Epitopes to Achieve a Functional HIV Cure$499,920
DP2 · FY2023 · AI · contact PI
Exploiting Highly Networked CTL Epitopes to Achieve a Functional HIV Cure$180,545
DP2 · FY2023 · AI · contact PI
Exploiting Highly Networked CTL Epitopes to Achieve a Functional HIV Cure$499,920
DP2 · FY2022 · AI · contact PI
Exploiting Highly Networked CTL Epitopes to Achieve a Functional HIV Cure$499,920
DP2 · FY2021 · AI · contact PI
Exploiting Highly Networked CTL Epitopes to Achieve a Functional HIV Cure$499,920
DP2 · FY2020 · AI · contact PI
Leveraging CTLs targeting highly networked epitopes to suppress the latent HIV-1 reservoir$199,800
K08 · FY2020 · AI · contact PI
Leveraging CTLs targeting highly networked epitopes to suppress the latent HIV-1 reservoir$199,800
K08 · FY2019 · AI · contact PI